Clinical Trials of Investigational Medical Products (CTIMPs) for Wilson's Disease

Comprehensive details about Clinical Trials, past present and future, can be accessed through the website https://clinicaltrials.gov/.  Simply type "Wilson's disease" into the box where it asks for Condition/Disease.  

Recruiting:

Orphalan – Phase 2 Study – Once a Day dosing of Trientine Tetrahydrochloride vs Standard of Care (SOC -  i.e. a patient’s current medication).

This Study is now live on https://clinicaltrials.gov/ and has the ID number NCT07010575.

Recruitment is underway for an 8 week study to explore Wilson's disease patients’ opinion on a new trientine formulation taken once a day vs SOC.

If you are aged 18 or older, have a Wilson’s disease diagnosis, take and have taken for at least 3 months no more than 1200 mg a day in divided doses of a WD chelating medication (i.e. penicillamine or a trientine product) and use contraception if you are sexually active, you may be eligible to participate in this Study.

This Study is run by a Virtual Clinical Research Centre (VCTC).  For further information, please telephone the VCTC on  01332 429760 (option 3) or email them on information@thevctc.com.